Benchling Stock
Private company — Benchling is privately held. Its shares are not listed on any public exchange and can only be accessed through private secondary transactions.
Status source: AXEVIL investment team
$5.77 per share (AXEVIL consensus estimate)
Source: AXEVIL consensus of recent secondary transactions · as of 11 August 2026
Valuation: $1.08B
Source: F, November 2021 — post-money $6.1B
Data last updated: 11 August 2026
About Benchling
Cloud platform for biotech R&D: an electronic lab notebook and data management for scientists. Its latest primary round was a $100M Series F in November 2021 at a $6.1B valuation; there have been no new primary rounds since, and secondary-market shares trade notably lower (around $3.9B). Annual recurring revenue is about $200M.
- Sector: Healthcare & Biotech
- Headquarters: San Francisco, USA
- Founded: 2012
Funding rounds
| Date | Round | Price / share | Post-money valuation |
|---|---|---|---|
| 18 November 2021 | F | $32.70 | $6.1B |
| 14 April 2021 | E | $23.22 | $4B |
| 28 May 2020 | D | $5.56 | $850M |
| 24 July 2019 | C | $2.85 | $375M |
| 14 June 2018 | B | $0.64 | $78M |
| 24 October 2016 | A | $0.45 | $38M |
| 15 April 2015 | Seed | $0.28 | $18M |
Latest news
Frequently asked questions
Can I buy Benchling stock?
Not on a public exchange — Benchling is privately held. Shares change hands only in private secondary transactions. AXEVIL structures those as dedicated US special purpose vehicles for accredited investors, subject to availability and to the rules of your jurisdiction.
How much is one Benchling share?
A private company has no single official price. AXEVIL's consensus estimate is $5.77 per share as of 11 August 2026. Its most recent round implied a post-money valuation of $6.1B (November 2021).
When will Benchling IPO?
No listing has been announced. AXEVIL does not forecast IPO dates — this page states what has actually been filed or reported, with the date it was last checked.
Is Benchling publicly traded?
No. Benchling is a private company and its shares are not listed on any public exchange.
Similar companies
- Neuralink — Healthcare & Biotech
Risk disclosure
Nothing on this page is an offer to sell or a solicitation to buy any security, and it is not investment advice. Valuations and share prices shown here are AXEVIL estimates built from primary sources — filings, announced rounds and completed secondary transactions — not quoted market prices, and they can be revised. Private-company shares are illiquid, may be impossible to sell, and the entire amount invested can be lost. Availability depends on your jurisdiction and on accredited-investor status.